| P2093 | author name string | David A Johnson | |
| P2860 | cites work | Prevalence of gastro-oesophageal reflux disease in general practice | Q28192956 |
| | Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use | Q28193290 |
| | Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease | Q31404948 |
| | Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis | Q33423526 |
| | Importance of pH control in the management of GERD. | Q33602987 |
| | Rabeprazole: a review of its use in acid-related gastrointestinal disorders | Q33768770 |
| | Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology | Q33864468 |
| | The proton-pump inhibitors: similarities and differences | Q33915562 |
| | Economic considerations in the treatment of gastroesophageal reflux disease: a review | Q34127313 |
| | Management of severe gastroesophageal reflux disease | Q34128740 |
| | Management of gastro-oesophageal reflux disease in general practice | Q34131661 |
| | Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician | Q34279878 |
| | Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole | Q34320782 |
| | Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole | Q34340193 |
| | Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease | Q34523308 |
| | Esomeprazole: a review of its use in the management of acid-related disorders in the US. | Q34621465 |
| | Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis | Q39428993 |
| | Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes | Q43622668 |
| | The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety | Q43650344 |
| | High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients | Q43701084 |
| | Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole | Q43742706 |
| | Pharmacokinetic study of esomeprazole in patients with hepatic impairment | Q43976464 |
| | Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers | Q44148251 |
| | The burden of selected digestive diseases in the United States | Q50113541 |
| | Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | Q52067661 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | esomeprazole | Q553223 |
| P304 | page(s) | 253-264 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Review of esomeprazole in the treatment of acid disorders | |
| P478 | volume | 4 | |